狄诺塞麦医保能给予报销吗？

It is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density.

On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. Denosumab was approved for the first time in 27 EU member states, as well as Norway, Iceland, and Liechtenstein. In June of the same year, denosumab was approved by the FDA for marketing.

So, can denosumab be reimbursed by medical insurance?

It is understood that denosumab has been on the market in China for only five months, so it is impossible to collect the domestic selling price of this drug, and there is no condition for medical insurance reimbursement!

Fortunately, denosumab produced by Amgen of the United States has been launched in Turkey. The specification is 125mg/1ml tube/box, and the price is equivalent to about 3,000 US dollars. It can be said to be high quality and low price. Due to the floating exchange rate, the price will be different. For specific prices, please consult Medical Companion Travel!

Denosumab is a drug that targets the RANK ligand. Compared with bisphosphonates that have been used clinically, denosumab has the advantage of significantly prolonging the time to occurrence of bone damage-related events. It can be administered subcutaneously and is easy to use. Clinical data shows that the drug does not require monitoring of renal function, while the use of bisphosphonates must be based on the patient's renal function monitoring. The dosing speed must be determined.

It has a high affinity with RANKL, prevents RANK ligand from activating RANK on the surface of osteoclasts, inhibits osteoclast activation and development, reduces bone resorption, increases bone density and bone strength of both cortical bone and trabecular bone, promotes bone reconstruction, and reduces the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women.